报价延迟最少15分钟:2026/10/24 09:23 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
27.99 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-5.87/-4.38
|
|
企业价值
2.17B
|
| 资产负债 |
|
每股账面净值
5.66
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. |
